학술논문
Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile
Document Type
article
Author
Jeffrey M. Sturek; Tania A. Thomas; James D. Gorham; Chelsea A. Sheppard; Allison H. Raymond; Kristen Petros De Guex; William B. Harrington; Andrew J. Barros; Gregory R. Madden; Yosra M. Alkabab; David Y. Lu; Qin Liu; Melinda D. Poulter; Amy J. Mathers; Archana Thakur; Dana L. Schalk; Ewa M. Kubicka; Lawrence G. Lum; Scott K. Heysell
Source
Microbiology Spectrum, Vol 10, Iss 1 (2022)
Subject
Language
English
ISSN
2165-0497
Abstract
ABSTRACT The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an unprecedented event requiring frequent adaptation to changing clinical circumstances. Convalescent immune plasma (CIP) is a promising treatment that can be mobilized rapidly in a pandemic setting. We tested whether administration of SARS-CoV-2 CIP at hospital admission could reduce the rate of ICU transfer or 28-day mortality or alter levels of specific antibody responses before and after CIP infusion. In a single-arm phase II study, patients >18 years-old with respiratory symptoms with confirmed COVID-19 infection who were admitted to a non-ICU bed were administered two units of CIP within 72 h of admission. Levels of SARS-CoV-2 detected by PCR in the respiratory tract and circulating anti-SARS-CoV-2 antibody titers were sequentially measured before and after CIP transfusion. Twenty-nine patients were transfused high titer CIP and 48 contemporaneous comparable controls were identified. All classes of antibodies to the three SARS-CoV-2 target proteins were significantly increased at days 7 and 14 post-transfusion compared with baseline (P